Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P39/00—General protective or antinoxious agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

• the present invention relates to pyrrolobenzodiazepines (PBDs), in particular
• pyrrolobenzodiazepines having a labile C2 protecting group, in the form of a linker to a cell binding agent.
• PBDs pyrrolobenzodiazepines
• Family members include abbeymycin (Hochlowski, et al., J. Antibiotics, 40, 145-148 (1987)), chicamycin (Konishi, et al., J. Antibiotics, 37, 200-206 (1984)), DC-81 (Japanese Patent 58-180 487; Thurston, et al., Chem. Brit, 26, 767-772 (1990); Bose, et al., Tetrahedron, 48, 751 -758 (1992)), mazethramycin (Kuminoto, et al., J.
• PBDs are of the general structure:
• WO 2007/085930 describes the preparation of dimer PBD compounds having linker groups for connection to a cell binding agent, such as an antibody.
• the linker is present in the bridge linking the monomer PBD units of the dimer.
• the present inventors have described dimer PBD compounds having linker groups for connection to a cell binding agent, such as an antibody, in WO 201 1/130613 and WO 201 1/130616.
• the linker in these compounds is attached to the PBD core via the C2 position, and are generally cleaved by action of an enzyme on the linker group.
• ADC antibody-drug conjugates
• cytotoxic or cytostatic agents i.e. drugs to kill or inhibit tumor cells in the treatment of cancer
• cytotoxic or cytostatic agents i.e. drugs to kill or inhibit tumor cells in the treatment of cancer
• systemic administration of these unconjugated drug agents may result in unacceptable levels of toxicity to normal cells
• Efforts to design and refine ADC have focused on the selectivity of monoclonal antibodies (mAbs) as well as drug mechanism of action, drug-linking, drug/antibody ratio (loading), and drug-releasing properties (Junutula, er a/., 2008b Nature Biotech., 26(8):925-932; Dornan et al (2009) Blood 1 14(13):2721 -2729; US 7521541 ; US 7723485; WO2009/052249; McDonagh (2006) Protein Eng. Design & Sel. 19(7): 299-307; Doronina et al (2006) Bioconj. Chem.
• Drug moieties may impart their cytotoxic and cytostatic effects by mechanisms including tubulin binding, DNA binding, proteasome and/or topoisomerase inhibition. Some cytotoxic drugs tend to be inactive or less active when conjugated to large antibodies or protein receptor ligands.
• the present inventors have developed particular PBD dimers with linking groups for the formation of PBD conjugates with cell binding agents, and in particular PBD antibody conjugates.
• the present invention provides a compound which is selected from A:
• WO 201 1/130615 discloses compound 26: which is the parent compound of A.
• Compound A comprises this PBD with a linker for attachment to a cell binding agent.
• the cell binding agent provides a number of ethylene glycol moieties to provide solubility which is useful in the synthesis of conjugates.
• WO 201 1/130613 also discloses com ound 51 :
• Compound B differs from compound 30 by only having a (CH 2 )3 tether between the PBD moieties, instead of a (CH 2 )5 tether, which reduces the lipophilicity of the released PBD dimer.
• the linking group is attached to the C2-phenyl group in the para rather than meta position.
• Compound C differs from this in two respects.
• the cell binding agent provides an increased number of ethylene glycol moieties to provide solubility which is useful in the synthesis of conjugates, and the phenyl substiuent provide two rather than one oxygen atom, which also aids solubility.
• Compound C's strucutre may also mean it binds more strongly in the minor groove.
• Compounds A, B and C have two sp 2 centres in each C-ring, which may allow for stronger binding in the minor groove of DNA, than for compounds with only one sp 2 centre in each C- ring.
• a second aspect of the present invention provides a conjugate of formula ConjA:
• CBA represents a cell binding agent.
• the link to the moiety shown is via a free S (active thiol) on the cell binding agent.
• the present invention provides a PBD dimer with a linker connected through the C2 position on one of the PBD moieties suitable for forming a PBD dimer conjugated via the linker to a cell binding agent.
• the present invention is suitable for use in providing a PBD compound to a preferred site in a subject.
• the conjugate allows the release of an active PBD compound that does not retain any part of the linker. There is no stub present that could affect the reactivity of the PBD mpound. Thus ConjA would release the compound RelA:
• a further aspect of the present invention is the compounds RelB, and salts and solvates thereof.
• a further aspect of the present invention is the compounds ReIC, and salts and solvates thereof.
• the speficied link between the PBD dimer and the cell binding agent, e.g. antibody, in the present invention is preferably stable extracellularly.
• the antibody-drug conjugate (ADC) is preferably stable and remains intact, i.e. the antibody remains linked to the drug moiety.
• the linkers are stable outside the target cell and may be cleaved at some efficacious rate inside the cell.
• An effective linker will: (i) maintain the specific binding properties of the antibody; (ii) allow intracellular delivery of the conjugate or drug moiety; (iii) remain stable and intact, i.e.
• Stability of the ADC may be measured by standard analytical techniques such as mass spectroscopy, HPLC, and the
• Delivery of the compounds of formulae RelA, RelB or ReIC is achieved at the desired activation site of the conjugates of formulae ConjA, ConjB or ConjC by the action of an enzyme, such as cathepsin, on the linking group, and in particular on the valine-alanine dipeptide moiety.
• an enzyme such as cathepsin
• a cell binding agent may be of any kind, and include peptides and non-peptides. These can include antibodies or a fragment of an antibody that contains at least one binding site, lymphokines, hormones, hormone mimetics, vitamins, growth factors, nutrient-transport molecules, or any other cell binding molecule or substance.
• the cell binding agent is a linear or cyclic peptide comprising 4-30, preferably 6-20, contiguous amino acid residues. In this embodiment, it is preferred that one cell binding agent is linked to one monomer or dimer pyrrolobenzodiazepine compound.
• the cell binding agent comprises a peptide that binds integrin ⁇ ⁇ ⁇ 6 .
• the peptide may be selective for ⁇ ⁇ ⁇ 6 over XYS.
• the cell binding agent comprises the A20FMDV-Cys polypeptide.
• the A20FMDV-Cys has the sequence: NAVPNLRGDLQVLAQKVARTC.
• a variant of the A20FMDV-Cys sequence may be used wherein one, two, three, four, five, six, seven, eight, nine or ten amino acid residues are substituted with another amino acid residue.
• polypeptide may have the sequence NAVXXXXXXXXXXXXXXXXXRTC.
• antibody herein is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies ⁇ e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity (Miller et al (2003) Jour, of Immunology 170:4854-4861 ).
• Antibodies may be murine, human, humanized, chimeric, or derived from other species.
• An antibody is a protein generated by the immune system that is capable of recognizing and binding to a specific antigen.
• a target antigen generally has numerous binding sites, also called epitopes, recognized by CDRs on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure. Thus, one antigen may have more than one corresponding antibody.
• An antibody includes a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule, i.e., a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease.
• a full-length immunoglobulin molecule or an immunologically active portion of a full-length immunoglobulin molecule i.e., a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease.
• immunoglobulin can be of any type (e.g. IgG, IgE, IgM, IgD, and IgA), class (e.g. lgG1 , lgG2, lgG3, lgG4, lgA1 and lgA2) or subclass of immunoglobulin molecule.
• the immunoglobulins can be derived from any species, including human, murine, or rabbit origin.
• Antibody fragments comprise a portion of a full length antibody, generally the antigen binding or variable region thereof.
• Examples of antibody fragments include Fab, Fab', F(ab') 2 , and scFv fragments; diabodies; linear antibodies; fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, CDR (complementary determining region), and epitope-binding fragments of any of the above which immunospecifically bind to cancer cell antigens, viral antigens or microbial antigens, single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
• the term "monoclonal antibody” as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e.
• Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be
• the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
• the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al (1975) Nature 256:495, or may be made by recombinant DNA methods (see, US 4816567).
• the monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al (1991 ) Nature, 352:624-628; Marks et al (1991 ) J. Mol. Biol., 222:581 -597 or from transgenic mice carrying a fully human immunoglobulin system (Lonberg (2008) Curr. Opinion 20(4):450-459).
• the monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (US 4816567; and Morrison et a/ (1984) Proc. Natl. Acad. Sci. USA, 81 :6851-6855).
• Chimeric antibodies include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non- human primate (e.g. Old World Monkey or Ape) and human constant region sequences.
• an “intact antibody” herein is one comprising a VL and VH domains, as well as a light chain constant domain (CL) and heavy chain constant domains, CH1 , CH2 and CH3.
• the constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof.
• the intact antibody may have one or more "effector functions" which refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1 q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and down regulation of cell surface receptors such as B cell receptor and BCR.
• intact antibodies can be assigned to different "classes.” There are five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into “subclasses” (isotypes), e.g., lgG1 , lgG2, lgG3, lgG4, IgA, and lgA2.
• the heavy-chain constant domains that correspond to the different classes of antibodies are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
• the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known. Humanisation
• a “humanized antibody” refers to a polypeptide comprising at least a portion of a modified variable region of a human antibody wherein a portion of the variable region, preferably a portion substantially less than the intact human variable domain, has been substituted by the corresponding sequence from a non-human species and wherein the modified variable region is linked to at least another part of another protein, preferably the constant region of a human antibody.
• the expression “humanized antibodies” includes human antibodies in which one or more complementarity determining region (“CDR”) amino acid residues and/or one or more framework region (“FW" or "FR”) amino acid residues are substituted by amino acid residues from analogous sites in rodent or other non-human antibodies.
• humanized antibody also includes an immunoglobulin amino acid sequence variant or fragment thereof that comprises an FR having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non- human immunoglobulin.
• “Humanized” forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. Or, looked at another way, a humanized antibody is a human antibody that also contains selected sequences from non-human (e.g. murine) antibodies in place of the human sequences.
• a humanized antibody can include conservative amino acid substitutions or non-natural residues from the same or different species that do not significantly alter its binding and/or biologic activity.
• Such antibodies are chimeric antibodies that contain minimal sequence derived from non- human immunoglobulins.
• the humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient antibody are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, camel, bovine, goat, or rabbit having the desired properties (in effect, the non- human CDRs are 'grafted' onto the human framework).
• CDR complementary-determining region
• donor antibody such as mouse, rat, camel, bovine, goat, or rabbit having the desired properties (in effect, the non- human CDRs are 'grafted' onto the human framework).
• framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues (this may happen when, for example, a particular FR residue has significant effect on antigen binding).
• humanized antibodies can comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance.
• a humanized antibody will comprise all of at least one, and in one aspect two, variable domains, in which all or all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.
• the humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), or that of a human immunoglobulin.
• the method consists of combining the V H or V L domain of a given non-human antibody specific for a particular epitope with a human V H or V L library and specific human V domains are selected against the antigen of interest. This selected human VH is then combined with a VL library to generate a completely human VHxVL combination. The method is described in Nature Biotechnology (N.Y.) 12, (1994) 899-903.
• two or more segments of amino acid sequence from a human antibody are combined within the final antibody molecule. They are constructed by combining multiple human VH and VL sequence segments in combinations which limit or avoid human T cell epitopes in the final composite antibody V regions. Where required, T cell epitopes are limited or avoided by, exchanging V region segments contributing to or encoding a T cell epitope with alternative segments which avoid T cell epitopes. This method is described in US 2008/0206239 A1.
• This method involves the removal of human (or other second species) T-cell epitopes from the V regions of the therapeutic antibody (or other molecule).
• the therapeutic antibodies V-region sequence is analysed for the presence of MHC class II- binding motifs by, for example, comparison with databases of MHC-binding motifs (such as the "motifs" database hosted at www.wehi.edu.au).
• MHC class II- binding motifs may be identified using computational threading methods such as those devised by Altuvia et al. (J. Mol. Biol. 249 244-250 (1995)); in these methods, consecutive overlapping peptides from the V-region sequences are testing for their binding energies to MHC class II proteins.
• This data can then be combined with information on other sequence features which relate to successfully presented peptides, such as amphipathicity, Rothbard motifs, and cleavage sites for cathepsin B and other processing enzymes.
• T-cell epitopes Once potential second species (e.g. human) T-cell epitopes have been identified, they are eliminated by the alteration of one or more amino acids.
• the modified amino acids are usually within the T-cell epitope itself, but may also be adjacent to the epitope in terms of the primary or secondary structure of the protein (and therefore, may not be adjacent in the primary structure). Most typically, the alteration is by way of substitution but, in some circumstances amino acid addition or deletion will be more appropriate.
• This method involves:
• step (c) defining for the non-human antibody to be humanized, a set of heavy and light chain surface exposed amino acid residues using the set of framework positions generated in step (b);
• step (d) identifying from human antibody amino acid sequences a set of heavy and light chain surface exposed amino acid residues that is most closely identical to the set of surface exposed amino acid residues defined in step (c), wherein the heavy and light chain from the human antibody are or are not naturally paired;
• step (e) substituting, in the amino acid sequence of the non-human antibody to be humanized, the set of heavy and light chain surface exposed amino acid residues defined in step (c) with the set of heavy and light chain surface exposed amino acid residues identified in step (d);
• step (f) constructing a three-dimensional model of the variable region of the non-human antibody resulting from the substituting specified in step (e);
• step (h) changing any residues identified in step (g) from the human to the original non- human amino acid residue to thereby define a non-human antibody humanizing set of surface exposed amino acid residues; with the proviso that step (a) need not be conducted first, but must be conducted prior to step (g).
• the method compares the non-human sequence with the functional human germline gene repertoire. Those human genes encoding canonical structures identical or closely related to the non-human sequences are selected. Those selected human genes with highest homology within the CDRs are chosen as FR donors. Finally, the non-human CDRs are grafted onto these human FRs. This method is described in patent WO 2005/079479 A2. Human String Content Optimization
• This method compares the non-human (e.g. mouse) sequence with the repertoire of human germline genes and the differences are scored as Human String Content (HSC) that quantifies a sequence at the level of potential MHC/T-cell epitopes.
• HSC Human String Content
• the target sequence is then humanized by maximizing its HSC rather than using a global identity measure to generate multiple diverse humanized variants (described in Molecular Immunology, 44, (2007) 1986-1998).
• the CDRs of the non-human antibody are fused in-frame to cDNA pools encompassing all known heavy and light chain human germline gene frameworks. Humanised antibodies are then selected by e.g. panning of the phage displayed antibody library. This is described in Methods 36, 43-60 (2005).
• cell binding agents include those agents described for use in WO 2007/085930, which is incorporated herein.
• Tumour-associate antigens and cognate antibodies for use in embodiments of the present invention are listed below. TUMOR-ASSOCIATED ANTIGENS AND COGNATE ANTIBODIES
• BMPR1B bone morphogenetic protein receptor-type IB
• NP_001 194 bone morphogenetic protein receptor, type IB /pid NP_001 194.1 .
• WO2004/032842 (Example IV); WO2003/042661 (Claim 12); WO2003/016475 (Claim 1 ); WO2002/78524 (Example 2); WO2002/99074 (Claim 19; Page 127-129); WO2002/86443 (Claim 27; Pages 222, 393); WO2003/003906 (Claim 10; Page 293); WO2002/64798 (Claim 33; Page 93-95); WO2000/14228 (Claim 5; Page 133-136); US2003/224454 (Fig 3);
• Sema 5b (FLJ10372, KIAA 1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, 25 sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B)
• WO2003/003984 (Claim 1 ); WO2002/06339 (Claim 1 ; Page 50); WO2001/88133 (Claim 1 ; Page 41 -43, 48-58); WO2003/054152 (Claim 20); WO2003/101400 (Claim 1 1 ); Accession: 30 Q9P283; Genew; HGNC:10737
• PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene)
• Genbank record update date Mar 1 1 , 2010 02:26 AM
• Genbank record update date Mar 1 1 , 2010 02:26 AM
• WO2004/048938 Example 2; WO2004/040000 (Claim 151 ); WO2003/087768 (Claim 1 ); 20 WO2003/016475 (Claim 1 ); WO2003/016475 (Claim 1 ); WO2002/61087 (Fig 1 );
• WO2003/104275 (Claim 1 ); WO2004/046342 (Example 2); WO2003/042661 (Claim 12); WO2003/083074 (Claim 14; Page 61 ); WO2003/018621 (Claim 1 ); WO2003/024392 (Claim 2; Fig 93); WO2001/66689 (Example 6); LocuslD:54894.
• STEAP2 HGNC_8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein
• Genbank record update date Mar 1 1 , 2010 01 :54 AM
• Genbank record update date Mar 1 1 , 2010 01 :54 AM
• WO2003/104270 (Claim 1 1 ); WO2003/104270 (Claim 16); US2004/005598 (Claim 22); WO2003/042661 (Claim 12); US2003/060612 (Claim 12; Fig 10); WO2002/26822 (Claim 23; Fig 2); WO2002/16429 (Claim 12; Fig 10); Gl:22655488.
• TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation 5 channel, subfamily M, member 4)
• Genbank record update date Jun 29, 2012 1 1 :27 AM
• Genbank record update date Jun 29, 2012 1 1 :27 AM
• WO2000/40614 (Claim 14; Page 100-103); WO2002/10382 (Claim 1 ; Fig 9A); WO2003/042661 (Claim 12); WO2002/30268 (Claim 27; Page 391 ); US2003/219806 (Claim 4); WO2001/62794 (Claim 10 14; Fig 1A-D); MIM:606936.
• WO2002/16413 (Claim 1 ; Page 94-95, 105); WO2002/22808 (Claim 2; Fig 1 ); US5854399 (Example 2; Col 17-18); US5792616 (Fig 2); M I M: 187395.
• CD21 CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs.73792)
• CD79b CD79B, ⁇ 79 ⁇ , IGb (immunoglobulin-associated beta), B29
• Genbank record update date Jun 26, 2012 01 :53 PM
• Genbank record update date Jun 26, 2012 01 :53 PM
• FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein 5 1a), SPAP1B, SPAP1C)
• WO2003/089904 (Claim 9); WO2003/016475 (Claim 1 ); US2003/1 18592; WO2003/008537 (Claim 1 ); WO2003/055439 (Claim 29; Fig 1A-B); WO2003/025228 (Claim 37; Fig 5C); 20 WO2002/22636 (Example 13; Page 95-107); WO2002/12341 (Claim 68; Fig 7);
• WO2002/13847 (Page 71 -74); WO2002/14503 (Page 1 14-1 17); WO2001/53463 (Claim 2; Page 41 -46); WO2001/41787 (Page 15); WO2000/44899 (Claim 52; Fig 7); WO2000/20579 (Claim 3; Fig 2); US5869445 (Claim 3; Col 31 -38); WO9630514 (Claim 2; Page 56-61 ); EP1439393 (Claim 7); WO2004/043361 (Claim 7); WO2004/022709; WO2001/00244 25 (Example 3; Fig 4); Accession: P04626; EMBL; M1 1767; AAA35808.1 . EMBL; M1 1761 ; AAA35808.1
• an antibody comprising CDRs having overall at least 80% sequence identity to CDRs having amino acid sequences of SEQ ID NO:3 (CDR-H1 ), SEQ ID NO:4 (CDR-H2), SEQ ID NO:5 (CDR-H3), SEQ ID NO:104 and/or SEQ ID NO:6 (CDR-L1 ), SEQ ID NO:7 (CDR-L2), and SEQ ID NO:8 (CDR-L3), wherein the anti- HER2 antibody or anti-HER2 binding fragment has reduced immunogenicity as compared to an antibody having a VH of SEQ ID NO:1 and a VL of SEQ ID NO:2.
• Biogen US201001 1951 1
• a purified antibody molecule that binds to HER2 comprising a all six CDR's from an antibody selected from the group consisting of BIIB71 F10 (SEQ ID NOs:1 1 , 13), BIIB69A09 (SEQ ID NOs:15, 17); BIIB67F10 (SEQ ID NOs:19, 21 );
• BIIB67F1 1 (SEQ ID NOs:23, 25), BIIB66A12 (SEQ ID NOs:27, 29), BIIB66C01 (SEQ ID NOs:31 , 33), BIIB65C10 (SEQ ID NOs:35, 37), BIIB65H09 (SEQ ID NOs:39, 41 ) and BIIB65B03 (SEQ ID NOs:43, 45), or CDRs which are identical or which have no more than two alterations from said CDRs.
• Herceptin (Genentech) - US6,054,297; ATCC accession no. CRL-10463 (Genentech)
• an antibody comprising a light chain amino acid sequence selected from SEQ ID No. 15 and 23, and a heavy chain amino acid sequence selected from SEQ ID No. 16 and 24
• an antibody comprising the amino acid sequence in SEQ ID No. 23, or a deamidated and/or oxidized variant thereof.
• an antibody having a light chain variable domain comprising the hypervariable regions of SEQ ID NO: 1 ".
• an antibody having a heavy chain variable domain comprising the hypervariable regions of SEQ ID NO: 2.
• WO2002/86443 (Claim 27; Page 427); WO2002/60317 (Claim 2); Accession: P40199; Q14920; EMBL; M29541 ; AAA59915.1.
• EP1394274 (Example 11); US2004/005320 (Example 5); WO2003/029262 (Page 74-75); WO2003/002717 (Claim 2; Page 63); WO2002/22153 (Page 45-47); US2002/042366 (Page 20-21); WO2001/46261 (Page 57-59); WO2001/46232 (Page 63-65); W098/37193 (Claim 1; Page 55-59); Accession: Q9UHF4; Q6UWA9; Q96SH8; EMBL; AF184971; AAF01320.1.
• WO2003042661 (Claim 12); WO200053216 (Claim 1 ; Page 41 ); WO2004065576 (Claim 1 ); WO2004020583 (Claim 9); WO2003004529 (Page 128-132); WO200053216 (Claim 1 ; Page 42); MIM:600997. (23) ASLG659 (B7h)
• Genbank record update date Jan 26, 201 1 07:37 AM
• WO2002/102235 (Claim 13; Page 299); US2003/091580 (Example 2); WO2002/10187 (Claim 6; Fig 10); WO2001/94641 (Claim 12; Fig 7b); WO2002/02624 (Claim 13; Fig 1A-1 B);
• Genbank record update date Feb 1 , 201 1 1 1 :25 AM
• Genbank record update date Feb 1 , 201 1 1 1 :25 AM
• Genbank record update date Mar 1 1 , 2010 02:24 AM
• Genbank record update date Mar 1 1 , 2010 02:24 AM
• AP14954 lipoma HMGIC fusion-partnerlike protein /pid AAP14954.1 - Homo sapiens (human); WO2003/054152 (Claim 20); WO2003/000842 (Claim 1 ); WO2003/023013 (Example 3, Claim 20); US2003/194704 (Claim 45); Gl:30102449; (26) BAFF-R (B cell -activating factor receptor, BLyS receptor 3, BR3)
• BAFF receptor /pid NP_443177.1 - Homo sapiens: Thompson, J.S., et al Science 293 (5537), 2108-21 1 1 (2001 ); WO2004/058309; WO2004/01 161 1 ; WO2003/045422 (Example; Page 32-33); WO2003/014294 (Claim 35; Fig 6B); WO2003/035846 (Claim 70; Page 615- 616); WO2002/94852 (Col 136-137); WO2002/38766 25 (Claim 3; Page 133);
• WO2002/24909 (Example 3; Fig 3); MIM:606269; NP_443177.1 ; NM_052945_1 ; AF132600 (27) CD22 (B-cell receptor CD22-B isoform, BL-CAM, Lyb-8, Lyb8, SIGLEC-2, FLJ22814) Nucleotide
• Genbank record update date Sep 1 1 , 2006 1 1 :24 PM
• Genbank record update date Sep 1 1 , 2006 1 1 :24 PM
• Genbank record update date Feb 2, 201 1 10:09 AM
• Genbank record update date Feb 2, 201 1 10:09 AM
• SIGLEC-2 SIGLEC2
• B-cell receptor CD22 B-lymphocyte cell adhesion molecule
• B-lymphocyte cell adhesion molecule BL- CAM
• CD22 antigen T-cell surface antigen Leu-14
• sialic acid binding Ig-like lectin 2 sialic acid-binding Ig-like lectin 2
• G5/44 (Inotuzumab): DiJoseph JF.,et al Cancer Immunol Immunother. 2005 Jan;54(1 ):1 1- 24.
• CD79a (CD79A, CD79alpha), immunoglobulin-associated alpha, a B cell-specific protein that covalently interacts with Ig beta (CD79B) and forms a complex on the surface with Ig M
• Genbank record update date Jun 26, 2012 01 :48 PM
• Genbank record update date Jun 26, 2012 01 :48 PM
• CXCR5 Bokitt's lymphoma receptor 1, a G protein-coupled receptor that is activated by the CXCL13 chemokine, functions in lymphocyte migration and humoral defense, plays a 10 role in HIV-2 infection and perhaps development of AIDS, lymphoma, myeloma, and leukemia); 372 aa, pi: 8.54 MW: 41959 TM: 7 [P] Gene Chromosome: 11q23.3,
• HLA-DOB Beta subunit of MHC class II molecule (la antigen) that binds peptides and 20 presents them to CD4+ T lymphocytes); 273 aa, pi: 6.56, MW: 30820. TM: 1 [P] Gene
• P2X5 Purinergic receptor P2X ligand-gated ion channel 5, an ion channel gated by extracellular ATP, may be involved in synaptic transmission and neurogenesis, deficiency may contribute to the pathophysiology of idiopathic detrusor instability
• 422 aa pi: 7.63, MW: 47206 TM: 1 [P] Gene Chromosome: 17p13.3).
• CD72 B-cell differentiation antigen CD72, Lyb-2
• Genbank record update date Jun 26, 2012 01 :43 PM
• Genbank record update date Jun 26, 2012 01 :43 PM
• WO2004042346 (claim 65); WO2003/026493 (pages 51-52, 57-58); WO2000/75655 (pages 105-106); Von Hoegen et a/ (1990) J. Immunol. 144(12):4870-4877; Strausberg et a I ⁇ 2002) Proc. Natl. Acad. Sci USA 99:16899-16903.
• LY64 Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family, regulates B-cell activation and apoptosis, loss of function is associated with increased disease activity in patients with systemic lupus erythematosis); 661 aa, pi: 6.20, MW: 74147 TM: 1 [P] Gene Chromosome: 5q12).
• FcRH1 Fc receptor-like protein 1, a putative receptor for the immunoglobulin Fc domain that contains C2 type Ig-like and IT AM domains, may have a role in B-lymphocyte
• IRTA2 Immunoglobulin superfamily receptor translocation associated 2, a putative immunoreceptor with possible roles in B cell development and lymphomagenesis
• Genbank record update date Mar 1 1 , 2010 01 :16 AM Polypeptide
• Genbank record update date Mar 1 1 , 2010 01 :16 AM
• TENB2 (TMEFF2, tomoregulin, TPEF, HPP1, TR, putative transmembrane
• 35 proteoglycan related to the EGF/heregulin family of growth factors and follistatin); 374 aa)
• Genbank record update date Mar 1 1 , 2010 01 :05 AM
• Genbank record update date Mar 1 1 , 2010 01 :05 AM
• N-acetylated alpha-linked acidic dipeptidase 1 N-acetylated-alpha- linked acidic dipeptidase I; NAALADase I; cell growth-inhibiting gene 27 protein; folylpoly- gamma-glutamate carboxypeptidase; glutamate carboxylase II; glutamate carboxypeptidase 2; glutamate carboxypeptidase II; membrane glutamate carboxypeptidase; prostate specific membrane antigen variant F; pteroylpoly-gamma-glutamate carboxypeptidase ANTIBODIES US 7,666,425:
• Antibodies produces by Hybridomas having the following ATCC references:ATCC accession No. HB-12101 , ATCC accession No. HB-12109, ATCC accession No. HB-12127 and ATCC accession No. HB-12126.
• ProScan a monoclonal antibody selected from the group consisting of 8H12, 3E1 1 , 17G1 , 29B4, 30C1 and 20F2 (US 7,81 1 ,564; Moffett S., et al Hybridoma (Larchmt). 2007
• Cytogen monoclonal antibodies 7E1 1-C5 (ATCC accession No. HB 10494) and 9H 10-A4 (ATCC accession No. HB1 1430) - US 5,763,202
• GlycoMimetics NUH2 - ATCC accession No. HB 9762 (US 7, 135,301 )
• Mouse anti-PSMA antibodies include the 3F5.4G6, 3D7.1.1 , 4E10-1.14, 3E1 1 , 4D8, 3E6, 3C9, 2C7, 1 G3, 3C4, 3C6, 4D4, 1 G9, 5C8B9, 3G6, 4C8B9, and monoclonal antibodies.
• Hybridomas secreting 3F5.4G6, 3D7.1 .1 , 4E10-1.14, 3E1 1 , 4D8, 3E6, 3C9, 2C7, 1 G3, 3C4, 3C6, 4D4, 1 G9, 5C8B9, 3G6 or 4C8B9 have been publicly deposited and are described in U.S. Pat. No. 6, 159,508. Relevant hybridomas have been publicly deposited and are described in U.S. Pat. No. 6, 107,090. Moreover, humanized anti-PSMA antibodies, including a humanized version of J591 , are described in further detail in PCT Publication WO
• mouse anti-human PSMA antibodies have been described in the art, such as mAb 107-1A4 (Wang, S. et al. (2001 ) Int. J. Cancer 92:871 -876) and mAb 2C9 (Kato, K. et al. (2003) Int. J. Urol. 10:439-444).
• human anti-PSMA monoclonal antibodies include the 4A3, 7F12, 8C12, 8A1 1 , 16F9, 2A10, 2C6, 2F5 and 1 C3 antibodies, isolated and structurally characterized as originally described in PCT Publications WO 01/09192 and WO 03/064606 and in U.S. Provisional Application Ser. No. 60/654,125, entitled “Human Monoclonal Antibodies to Prostate Specific Membrane Antigen (PSMA)", filed on Feb. 18, 2005.
• the V.sub.H amino acid sequences of 4A3, 7F12, 8C12, 8A1 1 , 16F9, 2A10, 2C6, 2F5 and 1 C3 are shown in SEQ ID NOs: 1-9, respectively.
• the V.sub.L amino acid sequences of 4A3, 7F12, 8C12, 8A1 1 , 16F9, 2A10, 2C6, 2F5 and 1 C3 are shown in SEQ ID NOs: 10-18, respectively.
• PSMA Development Company- Compositions of PSMA antibodies (US 20080286284, Table 1 )
• integrin alphaVbeta3 integrin, alpha V (vitronectin receptor, alpha polypeptide, antigen CD51 ); vitronectin receptor subunit alpha
• Biogen US 7,943,742 - Hybridoma clones 6.3G9 and 6.8G6 were deposited with the ATCC, accession numbers ATCC PTA-3649 and -3645, respectively. Biogen: US7,465,449 - In some embodiments, the antibody comprises the same heavy and light chain polypeptide sequences as an antibody produced by hybridoma 6.1A8, 6.3G9, 6.8G6, 6.2B1 , 6.2B10, 6.2A1 , 6.2E5, 7.1 G10, 7.7G5, or 7.1 C5. Centocor (J&J): US7,550, 142; US7, 163,681
• CEACAM5 Carcinoembryonic antigen-related cell adhesion molecule 5
• CDRs with the following sequences: heavy chain; CDR1 - DNYMH, CDR2 - WIDPENGDTE YAPKFRG, CDR3 - LIYAGYLAMD Y; and light chain CDR1 - SASSSVTYMH, CDR2 - STSNLAS, CDR3 - QQRSTYPLT.
• an antibody comprising the heavy chain variable region sequence from the amino acid sequence of SEQ ID NO: 1 , and the light chain variable region sequence from the amino acid sequence of SEQ ID NO:2.
• an antibody comprising the heavy chain variable region sequence from the amino acid sequence of SEQ ID NO:5, and the light chain variable region sequence from the amino acid sequence of SEQ ID NO:6.
• an antibody having CDRs of the light chain variable region comprise: CDR1 comprises KASQDVGTSVA (SEQ ID NO: 20); CDR2 comprises WTSTRHT (SEQ ID NO: 21 ); and CDR3 comprises QQYSLYRS (SEQ ID NO: 20).
• CDR1 comprises TYWMS (SEQ ID NO: 23);
• CDR2 comprises EIHPDSSTINYAPSLKD (SEQ ID NO: 24); and
• CDR3 comprises LYFGFPWFAY (SEQ ID NO: 25).
• HGF receptor HGF/SF receptor
• SF receptor hepatocyte growth factor receptor
• met proto-oncogene tyrosine kinase proto-oncogene c-Met
• scatter factor receptor tyrosine-protein kinase Met ANTIBODIES
• ATCC American Type Culture Collection
• an antibody comprising the sequences of CDR1 , CDR2 and
• CDR3 of heavy chain 4687 wherein the sequences of CDR1 , CDR2, and CDR3 of heavy chain 4687 are residues 26-35, 50-65, and 98-102, respectively, of SEQ ID NO: 58; and the sequences of CDR1 , CDR2, and CDR3 of light chain 5097, wherein the sequences of CDR1 , CDR2, and CDR3 oflight chain 5097 are residues 24-39,55-61 , and 94-100 of SEQ ID NO: 58; and the sequences of CDR1 , CDR2, and CDR3 of light chain 5097, wherein the sequences of CDR1 , CDR2, and CDR3 oflight chain 5097 are residues 24-39,55-61 , and 94-100 of SEQ ID
• DF3 antigen H23 antigen; breast carcinoma-associated antigen DF3; carcinoma-associated mucin; episialin; krebs von den Lungen-6; mucin 1 , transmembrane; mucin-1 ; peanut-reactive urinary mucin; polymorphic epithelial mucin; tumor associated epithelial mucin; tumor-associated epithelial membrane antigen; tumor-associated mucin ANTIBODIES
• AltaRex- Quest Pharma Tech US 6,716,966 - for example an Alt-1 antibody produced by the hybridoma ATCC No PTA-975.
• antibody MJ-170 hybridoma cell line MJ-170 ATCC
• accession no. PTA-5286Monoclonal antibody MJ-171 hybridoma cell line
• Genbank record update date Feb 2, 201 1 10:15 AM
• Genbank record update date Feb 2, 201 1 10:15 AM
• hybridoma VU-M75 which was deposited at the American Type Culture Collection under ATCC No. HB 1 128; or the V/10 monoclonal antibody secreted from the hybridoma V/10-VU, which was deposited at the International Depository Authority of the Belgian Coordinated Collection of Microorganisms (BCCM) at the Laboratorium voor Mole Les Bioloqie-
• LMBP Plasmidencollectie
• EGFRvlll Epidermal growth factor receptor (EGFR), transcript variant 3,
• a heavy chain variable region amino acid sequence selected from the group consisting of SEQ ID NO: 142 and variants & a light chain variable region amino acid sequence selected from the group consisting of: SEQ ID NO: 144 and variants.
• an antibody comprising a heavy chain amino acid sequence comprising:
• CDR1 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR1 region of antibodies 13.1 .2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 21 1 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17);
• CDR2 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR2 region of antibodies 13.1 .2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 21 1 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17); and
• CDR3 consisting of a sequence selected from the group consisting of the amino acid sequences for the CDR3 region of antibodies 13.1 .2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 21 1 (SEQ ID NO: 12), 124 (SEQ ID NO: 13), 318 (SEQ ID NO: 15), 342 (SEQ ID NO: 16), and 333 (SEQ ID NO: 17).
• an antibody having at least one of the heavy or light chain polypeptides comprises an amino acid sequence that is at least 90% identical to the amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 142, SEQ ID NO: 144, and any combination thereof.
• SEQ ID NO: 2 amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 142, SEQ ID NO: 144, and any combination thereof.
• antibody having heavy chain polypeptide and a light chain polypeptide, wherein at least one of the heavy or light chain polypeptides comprises an amino acid sequence that is at least 90% identical to the amino acid sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 142, SEQ ID NO: 144, and any combination thereof.
• an antibody heavy chain amino acid sequence selected from the group consisting of the heavy chain amino acid sequence of antibody 13.1 .2 (SEQ ID NO: 138), 131 (SEQ ID NO: 2), 170 (SEQ ID NO: 4), 150 (SEQ ID NO: 5), 095 (SEQ ID NO: 7), 250 (SEQ ID NO: 9), 139 (SEQ ID NO: 10), 21 1 (SEQ ID NO: 12), 124 (SEQ ID NO:
• a variant antibody having the sequence of SEQ ID NO.18 with the substitutions S98P-T99Y in the CDR3 VH, and F92W in CDR3 VL.
• SEQ ID NO:9 for antibody heavy chain variable region SEQ ID NO:9 for antibody heavy chain variable region
• SEQ ID NO:9 for antibody heavy chain variable region SEQ ID NO:9 for antibody heavy chain variable region
• SEQ ID NOs: 3 & 9 for light chain and heavy chain respectively
• CD33 (CD33 molecule)
• CD33 antigen gp67
• gp67 myeloid cell surface antigen CD33
• sialic acid binding Ig-like lectin 3 sialic acid-binding Ig-like lectin
• an antibody or fragment thereof comprising a heavy chain variable region which comprises three CDRs having the amino acid sequences of SEQ ID NOs:1 -3 and a light chain variable region comprising three CDRs having the amino acid sequences of SEQ ID NOs:4-6.
• CD19 CD19 molecule
• B-lymphocyte antigen CD19 B-lymphocyte surface antigen B4; T-cell surface antigen Leu-12; differentiation antigen CD19 ANTIBODIES
• an antibody comprising the sequence of hA19Vk (SEQ ID NO:7) and the sequence of hA19VH (SEQ ID NO: 10)
• an antibody or antigen-binding fragment thereof that comprises the light chain complementarity determining region CDR sequences CDR1 of SEQ ID NO: 16 (KASQSVDYDGDSYLN); CDR2 of SEQ ID NO: 17 (DASNLVS); and CDR3 of SEQ ID NO: 18 (QQSTEDPWT) and the heavy chain CDR sequences CDR1 of SEQ ID NO: 16 (KASQSVDYDGDSYLN); CDR2 of SEQ ID NO: 17 (DASNLVS); and CDR3 of SEQ ID NO: 18 (QQSTEDPWT) and the heavy chain CDR sequences CDR1 of SEQ ID NO:
• SYWMN SEQ ID NO: 19
• CDR2 of SEQ ID NO: 20 QIWPGDGDTNYNGKFKG
• CDR3 of SEQ ID NO: 21 RETTTVGRYYYAMDY
• FR human antibody framework
• substituted FR residues comprise the substitution of serine for phenylalanine at Kabat residue 91 of the heavy chain variable region.
• MorphoSys /Xencor MOR-208/XmAb-5574 - Zalevsky J., et al Blood. 2009 Apr
• IL2RA Interleukin 2 receptor, alpha
• NCBI Reference Sequence NM_000417.2
• an antibody having an antigen binding site comprises at least one domain which comprises CDR1 having the amino acid sequence in SEQ. ID. NO: 7, CDR2 having the amino acid sequence in SEQ. ID. NO: 8, and CDR3 chaving the amino acid sequence in SEQ. ID. NO: 9; or said CDR1 , CDR2 and CDR3 taken in sequence as a whole comprise an amino acid sequence which is at least 90% identical to SEQ. ID. NOs: 7, 8 and 9 taken in sequence as a whole.
• AXL AXL receptor tyrosine kinase
• CD30 - TNFRSF8 Tumor necrosis factor receptor superfamily, member 8
• CD30L receptor CD30L receptor
• Ki-1 antigen CD30
• cytokine receptor CD30 cytokine receptor CD30
• lymphocyte activation antigen CD30
• BCMA B-cell maturation antigen
• TNFRSF17 Tumor necrosis factor receptor superfamily, member 17
• Genbank record update date Feb 02, 201 1 10:40 AM
• BCM, BCMA, CD269 Other Designations: B cell maturation antigen; B-cell maturation factor; B-cell maturation protein; tumor necrosis factor receptor superfamily member 17
• CLEC14A C-type lectin domain family 14, member A; Genbank accession no.
• Genbank record update date Apr 01 , 2012 03:34 PM
• C-type lectin domain family 14 member A CIECT and EGF-like domain containing protein
• epidermal growth factor receptor 5 CIECT and EGF-like domain containing protein
• GRP78 - HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) Nucleotide
• CD27 ligand CD27-L; CD70 antigen; Ki-24 antigen; surface antigen CD70; tumor necrosis factor (ligand) superfamily, member 7; tumor necrosis factor ligand superfamily member 7
• E-NPP 3 dJ1005H1 1.3 (phosphodiesterase l/nucleotide pyrophosphatase 3); dJ914N13.3 (phosphodiesterase l/nucleotide pyrophosphatase 3); ectonucleotide pyrophosphatase/phosphodiesterase family member 3; gp130RB13-6; phosphodiesterase I beta; phosphodiesterase l/nucleotide pyrophosphatase 3;
• GCC - GUCY2C guanylate cyclase 2C (heat stable enterotoxin receptor)
• Genbank record update date Sep 02, 2012 01 :50 PM
• LIV-1 protein estrogen regulated
• ZIP-6 estrogen-regulated protein LIV-1
• solute carrier family 39 metal ion transporter
• solute carrier family 39 member 6 zinc transporter ZIP6
• zrt- and Irt-like protein 6 (63) 574, Trophoblast glycoprotein, TPBG - TPBG (trophoblast glycoprotein) Nucleotide
• Genbank record update date Feb 01 , 201 1 10:27 AM
• Genbank record update date Feb 01 , 201 1 10:27 AM

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Cell Biology (AREA)
• Oncology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Hematology (AREA)
• Toxicology (AREA)
• Peptides Or Proteins (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Priority Applications (25)

Applications Claiming Priority (2)

Publications (1)

Family

ID=49474386

Family Applications (1)

Country Status (24)

Cited By (64)

Families Citing this family (17)

Citations (19)

Family Cites Families (111)

• 2013
  • 2013-10-11 ES ES13780099T patent/ES2713164T3/es active Active
  • 2013-10-11 PL PL13780099T patent/PL2906248T3/pl unknown
  • 2013-10-11 KR KR1020157009875A patent/KR20150083994A/ko not_active Ceased
  • 2013-10-11 NZ NZ745069A patent/NZ745069A/en unknown
  • 2013-10-11 PL PL18187765T patent/PL3470086T3/pl unknown
  • 2013-10-11 TR TR2019/02494T patent/TR201902494T4/tr unknown
  • 2013-10-11 MX MX2015004560A patent/MX362004B/es active IP Right Grant
  • 2013-10-11 JP JP2015536139A patent/JP6367811B2/ja active Active
  • 2013-10-11 HU HUE13780099A patent/HUE043738T4/hu unknown
  • 2013-10-11 US US14/051,717 patent/US9415117B2/en active Active
  • 2013-10-11 LT LTEP18187765.5T patent/LT3470086T/lt unknown
  • 2013-10-11 LT LTEP13780099.1T patent/LT2906248T/lt unknown
  • 2013-10-11 SM SM20190144T patent/SMT201900144T1/it unknown
  • 2013-10-11 WO PCT/EP2013/071235 patent/WO2014057073A1/en not_active Ceased
  • 2013-10-11 AU AU2013328674A patent/AU2013328674B2/en active Active
  • 2013-10-11 HR HRP20190366TT patent/HRP20190366T1/hr unknown
  • 2013-10-11 NZ NZ705910A patent/NZ705910A/en unknown
  • 2013-10-11 HU HUE18187765A patent/HUE052835T2/hu unknown
  • 2013-10-11 CA CA3060520A patent/CA3060520C/en active Active
  • 2013-10-11 KR KR1020197032333A patent/KR102138220B1/ko active Active
  • 2013-10-11 CN CN201380053485.4A patent/CN104703630A/zh active Pending
  • 2013-10-11 SM SM20210265T patent/SMT202100265T1/it unknown
  • 2013-10-11 ES ES18187765T patent/ES2847050T3/es active Active
  • 2013-10-11 BR BR112015008251-3A patent/BR112015008251B1/pt active IP Right Grant
  • 2013-10-11 CN CN201910645725.9A patent/CN110256469B/zh active Active
  • 2013-10-11 SI SI201331845T patent/SI3470086T1/sl unknown
  • 2013-10-11 EP EP18187765.5A patent/EP3470086B1/en active Active
  • 2013-10-11 PT PT13780099T patent/PT2906248T/pt unknown
  • 2013-10-11 DK DK18187765.5T patent/DK3470086T3/da active
  • 2013-10-11 KR KR1020197038868A patent/KR20200003278A/ko not_active Ceased
  • 2013-10-11 RS RS20210002A patent/RS61294B1/sr unknown
  • 2013-10-11 CA CA2885315A patent/CA2885315C/en active Active
  • 2013-10-11 RS RS20190024A patent/RS58203B1/sr unknown
  • 2013-10-11 DK DK13780099.1T patent/DK2906248T3/en active
  • 2013-10-11 PT PT181877655T patent/PT3470086T/pt unknown
  • 2013-10-11 EP EP13780099.1A patent/EP2906248B1/en active Active
  • 2013-10-11 MX MX2018013577A patent/MX366303B/es unknown
  • 2013-10-11 SI SI201331325T patent/SI2906248T1/sl unknown
• 2015
  • 2015-03-16 ZA ZA2015/01781A patent/ZA201501781B/en unknown
• 2018
  • 2018-07-04 JP JP2018127804A patent/JP6516909B2/ja active Active
• 2019
  • 2019-02-26 CY CY20191100233T patent/CY1121390T1/el unknown
• 2021
  • 2021-01-22 HR HRP20210126TT patent/HRP20210126T1/hr unknown
  • 2021-02-04 CY CY20211100096T patent/CY1123778T1/el unknown

Patent Citations (20)

Non-Patent Citations (64)

Also Published As

Similar Documents

Legal Events